Free Trial
→ Ominous New Day in America (Get Ready for it) (From Weiss Ratings) (Ad)tc pixel
NASDAQ:OPK

OPKO Health Q3 2026 Earnings Date & Estimates

OPKO Health logo
$1.37 -0.02 (-1.44%)
Closing price 04:00 PM Eastern
Extended Trading
$1.37 0.00 (0.00%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OPKO Health is expected to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. The conference call is scheduled for October 28, 2026 at 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call Date
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from OPKO Health in Q3 2026

OPKO Health is expected to post earnings of -$0.07 per share on revenue of $136.62 million. In the same quarter a year earlier OPKO Health reported $0.03 per share on revenue of $151.67 million. OPKO Health last reported on July 27, 2026, posting -$0.01 per share and beating the -$0.08 consensus estimate. OPKO Health has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.07
Expected Revenue
$136.62 million
Prior-Year EPS
$0.03
Prior-Year Revenue
$151.67 million
Expected EPS Growth
-333.3%
Expected Revenue Growth
-9.9%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.01 (Beat by +$0.07)
Last Quarter Revenue
$163.58 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

OPKO Health Q3 2026 Earnings FAQ

OPKO Health (NASDAQ:OPK) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

OPKO Health's Q3 2026 earnings conference call is scheduled for Wednesday, October 28, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect OPKO Health to post earnings of -$0.07 per share for Q3 2026.

The consensus revenue estimate for OPKO Health is $136.62 million for Q3 2026.

OPKO Health Earnings Headlines

Here's Why You Should Retain WAT Stock in Your Portfolio for Now
October 8 at 3:13 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/heres-why-retain-wat-stock-131000312.html
10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research
October 8 at 3:13 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/10x-genomics-fred-hutch-join-132100363.html
This free guide explains options the way they should be taught
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before they ever place a trade. This free guide from Base Camp Trading takes a different approach, starting with the basics and showing you exactly how options work, why traders use them, and how they fit into a simple trading plan.tc pixel
October 8 at 1:00 AM  |  Base Camp Trading (Ad)
Bruker Gains 66.3% in a Year: What's Driving the Rally?
October 8 at 3:13 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/bruker-gains-66-3-whats-133900779.html
Reasons to Add Globus Medical Stock to Your Portfolio Now
October 7 at 1:42 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/reasons-add-globus-medical-stock-125100934.html
BDX Expands U.S. Manufacturing With $19B Healthcare Investment
October 7 at 1:42 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/bdx-expands-u-manufacturing-19b-145500480.html
See More OPKO Health Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OPKO Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OPKO Health and other key companies, straight to your email.

About OPKO Health

OPKO Health (NASDAQ:OPK) is a healthcare company focused on diagnostics and pharmaceuticals. Through its diagnostics businesses, the company provides laboratory services and specialized tests intended to support the detection, diagnosis and management of disease. Its operations include BioReference Health, a clinical laboratory business serving physicians, hospitals, employers and patients, as well as the 4Kscore test, which helps assess the risk of aggressive prostate cancer.

OPKO’s pharmaceutical business develops and commercializes treatments for conditions including kidney disease, endocrine disorders and growth-related conditions. Its products include Rayaldee, an extended-release formulation of calcifediol used to treat secondary hyperparathyroidism in adults with chronic kidney disease and vitamin D insufficiency. The company has also been involved in the development and commercialization of growth hormone therapies, including somatrogon, which is marketed in certain regions through a collaboration with Pfizer.

Headquartered in Miami, Florida, OPKO serves customers and patients in the United States and internationally through its laboratory, diagnostic and pharmaceutical activities. The company expanded its laboratory presence through the acquisition of Bio-Reference Laboratories in 2015. OPKO is led by Phillip Frost, who serves as executive chairman and chief executive officer.

View OPKO Health Profile
Earnings Tools